ライフサイエンスコーパス: letter

1 d their visual acuity (mean [SD], +3.8 [9.6] letters).

2 hy Study (approxETDRS) letters (range, 50-77 letters).

3 or other noninsulin medications (14.0+/-13.7 letters).

4 e not taking thiazolidinediones (13.2+/-13.3 letters).

5 n about their experience of receiving such a letter.

6 has now been amended in all versions of the Letter.

7 s used and was based on 52 interviews and 26 letters.

8 new sequence consisting of only two kinds of letters.

9 ained and 3 eyes (4%) lost 10 or more logMAR letters.

10 as 2.2 (12.5) (VISTA) and 3.8 (10.1) (VIVID) letters.

11 of the minimum angle of resolution (logMAR) letters.

12 ial to improve VA outcomes by a magnitude of letters.

13 ed to impaired perception of whole words and letters.

14 nimum interval of 4 months and if VA was <79 letters.

15 best-corrected visual acuity (BCVA) of >/=15 letters.

16 e and 58.2 letters at 1 year, a gain of +5.5 letters.

17 At 2 years, 17 subjects (5.8%) lost >/=15 letters.

18 f affected eyes visual acuity declined by 15 letters.

19 nt Diabetic Retinopathy Study vision of 68.4 letters.

20 encouraged to vote through get-out-the-vote letters.

21 Treatment Diabetic Retinopathy Study (ETDRS) letters.

22 ic findings) were gathered from the referral letters.

23 an increase in BCVA of 5 or more approxETDRS letters.

24 5 Early Treatment Diabetic Retinopathy Study letters.

25 red systemic therapy by 7.2 (95% CI, 2.1-12) letters.

26 The UDVA improved 4.5 logMAR letters.

27 +9.0 letters; PED absent at baseline, +11.3 letters), 0.5 mg PRN (present, +8.4; absent, +7.9), 2.0

28 t-corrected visual acuity in uveitic eyes (5 letters = 1 visual acuity chart line; potential range of

29 AI 2q4, IAI 2q8, and laser groups were +10.4 letters, +10.5 letters, and -0.7 letters at week 52 and

30 tters, and -0.7 letters at week 52 and +10.9 letters, +10.8 letters, and -0.8 letters at week 100, re

31 7 letters) in the binocular group and by 6.5 letters (2-sided 95% CI: 4.4-8.5 letters) in the patchin

32 blyopic eye VA improved from baseline by 3.5 letters (2-sided 95% confidence interval [CI]: 1.3-5.7 l

33 0.0001) and the per-protocol population (4.0 letters [2.4-5.7], p<0.0001).

34 Control condition (usual invitation letter) 2.

35 respectively, from a median baseline of 59.0 letters (20/63 Snellen equivalent).

36 , respectively, from a mean baseline of 58.9 letters (20/63 Snellen equivalent).

37 ine in the better-seeing eye was 67.2 (72.0) letters, 20/40- (20/40+) approximate Snellen conversion.

38 52, similar proportions of eyes gained >/=15 letters (31.5%-35.2%), whereas fewer eyes lost >/=5 lett

39 nd mean MV at baseline were 54.4 (+/- 15.26) letters, 490.16 (+/- 116.54) mum, and 10.46 (+/- 2.28) m

40 l acuity was 53.7 letters, improving to 58.8 letters (+5.1-letter gain) at 1 year.

41 In the study population (102 eyes), <5-letter, 5- to 9-letter, and >/=10-letter BCVA improvemen

42 (BCVA) at 3 months (logMAR equivalence of <5-letter, 5-9-letter, or >/=10-letter gain).

43 grade vitreous haze, gained an additional 42 letters (95% CI, 34-56 letters; P < 0.001) beyond the 13

44 erval [CI], 5.0-9.2) for bevacizumab and 8.4 letters (95% CI, 6.3-10.5) for ranibizumab, and a change

45 n the binocular and patching groups was -2.7 letters (95% CI: -5.7 to 0.3 letters, P = .082) or 0.5 l

46 average improvement in visual acuity of 7.1 letters (95% confidence interval [CI], 5.0-9.2) for beva

47 best corrected visual acuity difference 3.9 letters [95% CI 2.3-5.6], p<0.0001) and the per-protocol

48 .007) and lower baseline VALS (OR, 0.96 per letter; 95% CI, 0.94-0.98; P < .001) were associated wit

49 ment groups (implant vs. systemic therapy, 2 letters; 95% CI, -10 to 15 letters; P = 0.70).

50 vas, enabling the creation of shapes such as letters, a helicoid and a teddy bear.

51 S (intervention group) or a standard generic letter advertising the local SSS (control group).

52 ese eyes had a decline in visual acuity >/=5 letters after surgery.

53 enetic information has been stored in a four-letter alphabet that is propagated and retrieved by the

54 two protein sequences begin with strings of letters (amino acids) that represent the sequences, befo

55 ; minimal clinically important difference, 7 letters), analyzed by treatment assignment accounting fo

56 ing of participants to receipt of a personal letter and invitation to a taster session was not possib

57 receive either an individually tailored risk letter and invitation to attend a no-commitment introduc

58 r of the letter, the average position of the letter and the variation of the position of the letter a

59 Mean VA at 6 months was 38.3 ETDRS letters and 40.2 letters in the adjunct and control grou

60 At baseline mean VA and CRT were 50.7 letters and 631 mum respectively.

61 s specialized for the recognition of written letters and words.

62 oportion of eyes demonstrated suboptimal (<5-letter) and robust (>/=10-letter) early response to trea

63 tients taking thiazolidinediones (12.9+/-9.7 letters) and those not taking thiazolidinediones (13.2+/

64 dy population (102 eyes), <5-letter, 5- to 9-letter, and >/=10-letter BCVA improvements were seen in

65 , and laser groups were +10.4 letters, +10.5 letters, and -0.7 letters at week 52 and +10.9 letters,

66 letters at week 52 and +10.9 letters, +10.8 letters, and -0.8 letters at week 100, respectively.

67 demonstrated in eyes with baseline BCVA <69 letters, and associations remained significant after mul

68 The noninferiority margin was 5 letters, and statistical testing for noninferiority was

69 Learning to read causes the development of a letter- and word-selective region known as the visual wo

70 ter and the variation of the position of the letter appearing in the sequence.

71 Additionally, using a letter as a hidden image, we demonstrated the micro-SORS

72 etween the terms WORD and GENE, changing one letter at a time to yield a different, meaningful word (

73 r gain was 7.2 (P < .001) and 2.4 (P = .269) letters at 1 and 2 years, respectively, from a mean base

74 The median visual gain was 11.5 and 7.5 letters at 1 and 2 years, respectively, from a median ba

75 gures were 52.7 letters at baseline and 58.2 letters at 1 year, a gain of +5.5 letters.

76 early response (mean improvement 3.0 vs 13.8 letters at 156 weeks).

77 Delayed responders gained a median of 10 letters at 24 months, similar to immediate responders (1

78 6 Early Treatment Diabetic Retinopathy Study letters at 6 months (p = 0.15).

79 hm of the minimum angle of resolution or 3.5 letters at 6 months.

80 ry hypotheses were noninferiority (margin: 5 letters at a 1-sided alpha level 0.1) in best-corrected

81 eated eyes, the respective figures were 52.7 letters at baseline and 58.2 letters at 1 year, a gain o

82 The mean VA changed from 55.9 +/- 15 letters at baseline to 61.3 +/- 16.9 letters (VA gain 5.

83 han the prespecified acceptable margin of -5 letters at both 12 weeks and 52 weeks.

84 , making up for an initial difference of -45 letters at the preoperative visit (95% CI, -56 to -34 le

85 2 and +10.9 letters, +10.8 letters, and -0.8 letters at week 100, respectively.

86 GF monotherapy (10.6 compared with 6.5 ETDRS letters at week 24; P = 0.019).

87 were +10.4 letters, +10.5 letters, and -0.7 letters at week 52 and +10.9 letters, +10.8 letters, and

88 seline to 61.3 +/- 16.9 letters (VA gain 5.4 letters) at 1 year and to 61 +/- 17.1 letters (VA gain 5

89 to 61 +/- 17.1 letters (VA gain 5.1 +/- 14.9 letters) at 2 years.

90 ulation (340 eyes), <5-, 5- to 9-, and >/=10-letter BCVA improvements occurred in 39.7%, 23.2%, and 3

91 eyes), <5-letter, 5- to 9-letter, and >/=10-letter BCVA improvements were seen in 44.1%, 18.6%, and

92 The difference in change in crude VA of 0.6 letters between the 2 groups was not statistically signi

93 m baseline at month 6 (14.8 and 14.8 vs. 6.0 letters; both P < 0.0001; primary end point met).

94 Six eyes (13% N = 46) lost more than 10 letters by month 24.

95 wded window in the visual field within which letters can be recognizable reliably).

96 Motifs of only 1-4 letters can play important roles when present at key loc

97 nt judgment task) vs dual (switching between letter case and vowel/consonant decisions) task.

98 which task difficulty varied: single (either letter case or vowel/consonant judgment task) vs dual (s

99 All of the keratoplasty research articles, letters, case reports, reviews and meeting abstracts pub

100 with center-involving DME and VA </=79 ETDRS letters, central subfield macular thickness (CST) >/=350

101 Mean (SD) letter change in VA over 2 years (area under curve) was

102 We also evaluated 10- and 15-letter change on the ETDRS visual acuity chart.

103 In this letter, culture-independent diagnostic tests (CIDTs) for

104 nders group, 10476 patients), 495 received a letter describing region-specific CRC screening adherenc

105 ttery scores (Mini-Mental State Examination, Letter Digit Substitution Task, Word Fluency Test, Stroo

106 on the Trail Making Test parts A and B, the Letter Digit Substitution Test (LDST), the Digit Symbol

107 Letter-digit substitution (HR, 1.59; 95% CI, 1.22-2.04),

108 s were administered (Stroop color word test, letter-digit substitution, verbal fluency, and word lear

109 (Mini-Mental State Examination, Stroop Test, Letter-Digit-Substitution Test, Word Fluency Test), mood

110 clusion compared to 29% in the robust (>/=10-letter) early response group (P = .009).

111 ted suboptimal (<5-letter) and robust (>/=10-letter) early response to treatment at 3 months.

112 eenees with a negative FIT result received a letter explaining that no blood had been detected in the

113 We presented subjects with numbers, letters, false numbers, false letters, objects and their

114 core changes (+15.1, +14.2, +11.3, and +11.2 letters for >/=3-step improvement, >/=2-step improvement

115 ) decrease in visual acuity was 6.2 +/- 15.6 letters for patients with image data available.

116 demonstrated a root mean square error of 8.2 letters for predicted compared to actual visual acuity a

117 n the feedback intervention group was sent a letter from England's Chief Medical Officer and a leafle

118 e in VA was -3 letters from baseline and -11 letters from 2 years.

119 Mean change in VA was -3 letters from baseline and -11 letters from 2 years.

120 yed 15-letter responders (did not gain >/=15 letters from baseline at month 3 but did so at month 12)

121 as early 15-letter responders (gained >/=15 letters from baseline at month 3) or delayed 15-letter r

122 f 11.0 (10.1) (VISTA) and 10.0 (6.5) (VIVID) letters from baseline, and they subsequently gained a me

123 mproved in early tears before the tear (+5.6 letters from baseline; P = 0.01), decreased immediately

124 ed visual acuity (BCVA) improvement of >/=15 letters from preoperative baseline through day 14 mainta

125 e in study 2 had a BCVA improvement of >/=15 letters from preoperative baseline through day 90 (77.2%

126 atients (%) with a BCVA improvement of >/=15 letters from preoperative baseline through days 90 and 6

127 g during ENDURANCE, fluctuating by <1.5 mean letters from the baseline at all time points.

128 of 17.4 (9.7) (VISTA) and 13.6 (8.6) (VIVID) letters from the initiation of treatment with intravitre

129 Overall, visual acuity increased by 23 letters from the preoperative visit to the 3-month visit

130 Early Treatment Diabetic Retinopathy [ETDRS] letters) from baseline to 24 weeks.

131 CI, 34-56 letters; P < 0.001) beyond the 13-letter gain in eyes that had gradable vitreous haze befo

132 th 18 of those (39% N = 46) maintaining a 10-letter gain throughout the 24 months.

133 The mean letter gain was 7.2 (P < .001) and 2.4 (P = .269) letter

134 3.7 letters, improving to 58.8 letters (+5.1-letter gain) at 1 year.

135 uivalence of <5-letter, 5-9-letter, or >/=10-letter gain).

136 nt end points of visual benefit (>/=15 ETDRS letter gain, final VA >/=20/40 or >/=20/25) and visual l

137 r) responders at 3 months, 6.7% showed >/=10-letter gains at study conclusion compared to 29% in the

138 At 1 year, >/=10- and >/=15-letter gains in best-corrected visual acuity were observ

139 ined by life-table analyses, and at least 10 letter (>/=2 line) gain or loss of visual acuity among t

140 The original version of this Letter has been modified in the abstract and main text t

141 no eye with extrafoveal CNV experienced a 10-letter improvement at the 3-year examination.

142 The percentage of patients achieving a >/=15-letter improvement from baseline through day 14 maintain

143 white In all 4 cohorts, there was a 3- to 5-letter improvement in mean visual acuity over the 3 mont

144 int improvement in IND-VFQ score for every 5-letter improvement in visual acuity (95% CI: 1.9, 4.3; P

145 The mean baseline visual acuity was 53.7 letters, improving to 58.8 letters (+5.1-letter gain) at

146 In his famous letter in 1870, Maxwell describes how Joule's law can be

147 (3.3) letters in treated eyes and +0.8 (3.1) letters in control eyes.

148 RSS change, respectively) compared with +5.0 letters in patients who had any DRSS worsening.

149 2 letters in the YAG laser group and by -0.6 letters in sham group (difference, 0.4; 95% CI, -6.5 to

150 an improvement from baseline BCVA was +11.06 letters in the 0.5 mg RBZ group (n = 59) and +6.78 lette

151 s in the 0.5 mg RBZ group (n = 59) and +6.78 letters in the 2.0 mg RBZ group (n = 54) (P = 0.02).

152 at 6 months was 38.3 ETDRS letters and 40.2 letters in the adjunct and control groups, respectively.

153 the mean BCVA improved by 8.6, 9.6, and 9.5 letters in the Monthly, TREX, and GILA cohorts, respecti

154 ent in BCVA was 11.31+/-6.67 and 6.86+/-7.58 letters in the VMA+ and VMA- groups, respectively (P = 0

155 Best-corrected visual acuity changed by -0.2 letters in the YAG laser group and by -0.6 letters in sh

156 (SE) change in visual acuity was +5.4 (3.3) letters in treated eyes and +0.8 (3.1) letters in contro

157 At week 12, change from baseline BCVA (ETDRS letters) in Group 1 vs 2 was +11.6 vs +8.5 (P = .32) and

158 -sided 95% confidence interval [CI]: 1.3-5.7 letters) in the binocular group and by 6.5 letters (2-si

159 and by 6.5 letters (2-sided 95% CI: 4.4-8.5 letters) in the patching group.

160 ; Early Treatment Diabetic Retinopathy Study letters] in BCVA) after treatment with a DEX implant.

161 en patients taking only insulin (12.6+/-11.2 letters), insulin plus other medications (12.2+/-12.4 le

162 The purpose of the present letter is twofold.

163 atings, and near visual acuity measured with letters is lower than near visual acuity measured with s

164 h a robust early response demonstrated >/=10-letter long-term gain in BCVA at a significantly higher

165 tters (mean 68.8 +/- 11) at month 12 and 5.2 letters (mean 65.7 +/- 12.3) at 24 months compared to ba

166 ean best-corrected visual acuity gain of 8.3 letters (mean 68.8 +/- 11) at month 12 and 5.2 letters (

167 rmation arises from base pairing of the four-letter nucleobase code to form a double helix.

168 Cognition was measured by the Letter Number Span test and scales from the California V

169 ve control (Stroop task) and working memory (Letter-Number Sequencing (LNS) task).

170 with numbers, letters, false numbers, false letters, objects and their Fourier randomized versions.

171 with bereaved family members who received a letter of condolence and letters written by these family

172 A letter of condolence may help bereaved relatives, but li

173 dy also shows a common ambivalence about the letter of condolence's benefit.

174 ed family members' experience of receiving a letter of condolence.

175 st a loved one in the ICU and who received a letter of condolence.

176 study describes the benefits of receiving a letter of condolence; mainly, it humanizes the medical i

177 For each letter of each sequence we calculate the number of the l

178 May 18, 2014, we contacted 300 people with a letter of invitation.

179 o using the abbreviation ACC for the first 3 letters of Accessibility) is defined as an individual's

180 The proportion of eyes that gained >/=15 letters of BCVA by 1 year was similar for the 2 agents w

181 ete access to medical records and specialist letters of study participants.

182 us endophthalmitis retained vision within 10 letters of the pre-endophthalmitis level.

183 The results reported in this Letter offer a solution to the aforementioned problems o

184 onders receiving PRN treatment maintained 15-letter or greater gains at month 24.

185 ent Diabetic Retinopathy Study [ETDRS] of 55 letters or better); (2) cystoid macular edema (CMO), fov

186 and the proportion of eyes that gained >/=15 letters or lost >/=5 letters were evaluated in eyes with

187 eline vision with 23 eyes (41.1%) gaining 10 letters or more at month 12.

188 Improvement of 15 letters or more from baseline occurred in 266 (25.2%) of

189 A loss of 15 letters or more in BCVA was more common in patients with

190 rected visual acuity letter score gain of 15 letters or more was more common in patients with 2-step

191 easily combine to form a unique symbol (e.g. letters or objects), observers typically confuse the sou

192 insulin plus other medications (12.2+/-12.4 letters), or other noninsulin medications (14.0+/-13.7 l

193 months (logMAR equivalence of <5-letter, 5-9-letter, or >/=10-letter gain).

194 ed if they were review articles, editorials, letters, or case reports.

195 In the version of this Letter originally published, the authors incorrectly sta

196 VA change at 12 months was +6.6 (+/- 13.35) letters (P = .0003).

197 changes from week 12 BCVA and CST were +7.0 letters (P = .01) and -108.25 mum (P = .04).

198 s with neither CME nor IRF (52 vs. 60 vs. 66 letters, P < 0.001); higher mean total CRT (mum) on OCT

199 groups was -2.7 letters (95% CI: -5.7 to 0.3 letters, P = .082) or 0.5 lines, favoring patching.

200 ayed responders had worse BCVA (49.8 vs 55.4 letters; P < .001) and greater CFT (374.9 vs 339.0 micro

201 apy (mean average BCVA change: 15.4 vs. 15.0 letters; P < 0.0001).

202 to 212 and >212 mum (59.4 vs. 71.3 vs. 70.3 letters; P < 0.0001).

203 12.3 letters (standard deviation [SD], 16.72 letters; P < 0.0001).

204 ranibizumab from month 6; 17.3/15.5 vs. 11.6 letters; P < 0.0001).

205 e vitreous haze before surgery (95% CI, 9-18 letters; P < 0.001) 3 months after surgery, making up fo

206 h visit (95% confidence interval [CI], 17-29 letters; P < 0.001) and was stable through 9 months of f

207 ined an additional 42 letters (95% CI, 34-56 letters; P < 0.001) beyond the 13-letter gain in eyes th

208 n control eyes before tearing (55.5 vs. 66.9 letters; P < 0.001).

209 t the preoperative visit (95% CI, -56 to -34 letters; P < 0.001).

210 , decreased immediately after the tear (-8.3 letters; P = 0.002), then recovered with no difference c

211 mean VA than eyes with no SRF (72.8 vs. 66.6 letters; P = 0.006).

212 lost more VA than the bevacizumab group (-4 letters; P = 0.008).

213 arly compared with late tears (53.6 vs. 63.4 letters; P = 0.009).

214 ment from baseline was greater (10.6 vs. 6.9 letters; P = 0.01) at 1 year, but similar at 2 years (7.

215 months, similar to immediate responders (14 letters; P = 0.15).

216 1 year, but similar at 2 years (7.8 vs. 6.2 letters; P = 0.34).

217 stemic therapy, 2 letters; 95% CI, -10 to 15 letters; P = 0.70).

218 ne, eyes with HE had worse VA (mean 57 vs 61 letters; p=0.003), larger total lesion size (3.3 vs 2.4

219 s (i.e., the common co-occurrence of certain letter pairs), the edit distance between nonwords and wo

220 .5 mg monthly (PED present at baseline, +9.0 letters; PED absent at baseline, +11.3 letters), 0.5 mg

221 Treatment masking used 16 letters per 6-wk block in the randomisation process.

222 lectrode placement, at the equivalent of two letters per minute.

223 howed a significant improvement of 2.3 ETDRS letters per year (P < 0.001).

224 25 and 20/70 declined at a rate of 2.3 ETDRS letters per year (P = 0.002), eyes with baseline BCVA be

225 0 and 20/200 declined at a rate of 0.8 ETDRS letters per year (P = 0.08), and eyes with baseline BCVA

226 25 or better declined at a rate of 2.8 ETDRS letters per year (P = 0.10), eyes with baseline BCVA bet

227 This Letter presents the first observation on the interplay b

228 ent Diabetic Retinopathy Study (approxETDRS) letters (range, 50-77 letters).

229 ity chart line; potential range of change in letters read, -121 to +101; minimal clinically important

230 0 trials of the quick CSF method in a 10-AFC letter recognition task.

231 oss the central 16-degree visual field using letter-recognition tasks.

232 e-based interventions, the enhanced reminder letter reduced the socioeconomic gradient in screening u

233 ly Treatment of Diabetic Retinopathy (ETDRS)-letters, respectively.

234 ters from baseline at month 3) or delayed 15-letter responders (did not gain >/=15 letters from basel

235 tegorized based on BCVA outcomes as early 15-letter responders (gained >/=15 letters from baseline at

236 Among suboptimal (<5-letter) responders at 3 months, 6.7% showed >/=10-letter

237 baseline best-corrected visual acuity (BCVA) letter score >/=15 at week 24.

238 2 Early Treatment Diabetic Retinopathy Study letter score (20/40 Snellen equivalent).

239 ) Early Treatment Diabetic Retinopathy Study letter score (approximately 20/100 Snellen equivalent),

240 between NEI VFQ-25 scores with visual acuity letter score (VALS) and central retinal thickness; and c

241 utcome was mean change in visual acuity (VA) letter score (VALS) from the randomization visit to the

242 Change from baseline in VA letter score (VALS), VALS gain of 15 or more, change fro

243 e participants having baseline visual acuity letter score and OCT-measured central subfield thickness

244 Treatment Diabetic Retinopathy Study (ETDRS) letter score change, mean contrast sensitivity change, p

245 Mean best-corrected visual acuity (BCVA) letter score change, proportion of patients with 15 or m

246 ability or improvement had greater mean BCVA letter score changes (+15.1, +14.2, +11.3, and +11.2 let

247 Best-corrected visual acuity letter score gain of 15 letters or more was more common

248 corresponding mean change from baseline BCVA letter score was 17.0 versus 6.9 (P < 0.0001) at week 24

249 At baseline, mean visual acuity letter score was 50 (20/100) (range, 19-73 [20/400 to 20

250 Treatment Diabetic Retinopathy Study (ETDRS) letter scores, and diabetic retinopathy (DR) was measure

251 Treatment Diabetic Retinopathy Study (ETDRS) letter scores.

252 tely identify the 6/9.5 [LogMAR 0.2] line of letters/shapes with each eye and 86.6% the 6/6 line [Log

253 Through these letters, she detailed her experience as a woman professi

254 Learning to read involves the acquisition of letter-sound relationships (i.e., decoding skills) and t

255 Viewing distance, chart used, and letter spacing should be adapted to the child's developm

256 ch by successfully recovering an obliterated letter stamped with a pressure of approximately 170 MPa

257 in in BCVA from baseline at month 12 of 12.3 letters (standard deviation [SD], 16.72 letters; P < 0.0

258 (Early Treatment Diabetic Retinopathy Study letters +/- standard deviation) was not different betwee

259 The letter stated that the practice was prescribing antibiot

260 the VWFA can discriminate words from nonword letter strings (pseudowords); (2) the VWFA has preferent

261 n 5-y-old (n = 40) prereaders presented with letter strings appearing every five items in rapid strea

262 left hemispheric cortical specialization for letter strings is typically detected only after approxim

263 of the early left hemispheric dominance for letter strings.

264 .5% LCA of 2.7 (P = .022) and 3.1 (P = .014) letters than did those without near or distance stereoac

265 t baseline, eyes with CME had worse mean VA (letters) than eyes with IRF without CME and eyes with ne

266 organisms whose DNA harbours two additional letters that form a third, unnatural base pair.

267 each sequence we calculate the number of the letter, the average position of the letter and the varia

268 Disease Control and Prevention (CDC) sent a letter to state and territorial epidemiologists, state a

269 This Letter to the Editor clarifies the landscape approach as

270 We request to retract our Letter to the Editor entitled "DNAJC6 variants in Parkin

271 BCVA change from baseline of 6.2 versus 8.1 letters to the end of study, respectively.

272 in 5.4 letters) at 1 year and to 61 +/- 17.1 letters (VA gain 5.1 +/- 14.9 letters) at 2 years.

273 +/- 15 letters at baseline to 61.3 +/- 16.9 letters (VA gain 5.4 letters) at 1 year and to 61 +/- 17

274 eting prespecified criteria of at least a 10-letter visual acuity loss at 2 consecutive visits or at

275 oss at 2 consecutive visits or at least a 15-letter visual acuity loss from the best previous measure

276 The personal letter was generated by a research assistant, but the re

277 portion of participants losing fewer than 15 letters was 84% in the EMB arm and 92% in the ranibizuma

278 Mean change from baseline BCVA (letters) was 6.3+/-1.3 in the combination group, 5.7+/-1

279 In this letter we study thermodynamics of information using an e

280 In this letter, we combine high pressure and in situ laser heati

281 In this Letter, we demonstrate continuous-flow liquid microjunct

282 In this Letter, we demonstrate direct actuation of a radio-frequ

283 In this letter, we demonstrate that in the diffusive case, the c

284 In this letter, we propose an alternative, effective protocol fo

285 In this letter, we propose the use of machine-learning for predi

286 In this letter, we report the crystallization and phase transfor

287 uity (BCVA) in the treated eye of about 0.97 letters/week (p = 0.033).

288 ize and FS for achieving a BCVA >/= 70 ETDRS letters were detected (area 1: </=6 mm(2); area 2: >/=0.

289 eyes that gained >/=15 letters or lost >/=5 letters were evaluated in eyes with and without persiste

290 Letters were sent to 3227 GPs in the intervention group.

291 r" articles (eg, techniques, special topics, letters) were reviewed.

292 (referential or target) contains mixed-cased letters (which is the case for only the two Korean genom

293 ate and time (intervention) or an invitation letter with a telephone number to call to book their new

294 (31.5%-35.2%), whereas fewer eyes lost >/=5 letters with 2q4 compared with Rq4 and 2q8 (6.5% vs. 16.

295 uding mean (SD) improvements by +13.3 (11.1) letters with aflibercept vs +9.7 (10.1) letters with bev

296 1.1) letters with aflibercept vs +9.7 (10.1) letters with bevacizumab (P < .001) and +11.2 (9.4) lett

297 with bevacizumab (P < .001) and +11.2 (9.4) letters with ranibizumab (P = .03).

298 The mean BCVA change from baseline (letters) with brolucizumab was noninferior to aflibercep

299 We aimed to assess whether a GP's personal letter, with an evidence-based leaflet about overcoming

300 bers who received a letter of condolence and letters written by these family members to the ICU team.